Carregant...
Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU
Imatinib is an oral tyrosine kinase inhibitor and considered to be the most successful targeted anti-cancer agent yet developed given its substantial efficacy in treating chronic myeloid leukemia (CML) and other malignant diseases. In the USA and the European Union (EU), Novartis’ composition of mat...
Guardat en:
| Publicat a: | Ann Hematol |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4598066/ https://ncbi.nlm.nih.gov/pubmed/25814091 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-015-2319-x |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|